XLXin Ying Lim

Xin Ying Lim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xin Ying Lim has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

    by John E. Pimanda, Julie A.I. Thoms, Henry R. Hampton, Sarah Davidson, Swapna Joshi, Chowdhury H. Sarowar, Xin Ying Lim, Andrea C. Nunez, Purvi M. Kakadia, Russell Pickford, et al.

    Introduction: Hypomethylating agents (HMAs) are the mainstay of treatment for high-risk myelodysplasia (HR-MDS), chronic myelomonocytic leukemia (CMML) and low-

  • Acupuncture for the reduction of post-operative pain in a patient with symptomatic irreversible pulpitis: a case report

    by Kim Sia Sng, Yen Suan Sin, Shekhar Bhatia, Shivani Kohli, Xin Ying Lim, Jie Ying Ong


  • Open Access

    A selective inhibitor of ceramide synthase 1 reveals a novel role in fat metabolism

    by Nigel Turner, Xin Ying Lim, Hamish D. Toop, Brenna Osborne, Amanda E. Brandon, Elysha N. Taylor, Corrine E. Fiveash, Hemna Govindaraju, Jonathan D. Teo, Holly P. McEwen, et al.

    Specific forms of the lipid ceramide, synthesized by the ceramide synthase enzyme family, are believed to regulate metabolic physiology. Genetic mouse models have established C16 ceramide as a driver of insulin resistance in liver and adipose tissue. C18 ceramide, synthesized by ceramide synthase 1 (CerS1), is abundant in skeletal muscle and suggested to promote insulin resistance in humans. We herein describe the first isoform-specific ceramide synthase inhibitor, P053, which inhibits CerS1 with nanomolar potency. Lipidomic profiling shows that P053 is highly selective for CerS1. Daily P053 administration to mice fed a high-fat diet (HFD) increases fatty acid oxidation in skeletal muscle and impedes increases in muscle triglycerides and adiposity, but does not protect against HFD-induced insulin resistance. Our inhibitor therefore allowed us to define a role for CerS1 as an endogenous inhibitor of mitochondrial fatty acid oxidation in muscle and regulator of whole-body adiposity.


  • Regulation of glucose homeostasis and insulin action by ceramide acyl-chain length: A beneficial role for very long-chain sphingolipid species

    by Magdalene K. Montgomery, Simon H.J. Brown, Xin Y. Lim, Corrine E. Fiveash, Brenna Osborne, Nicholas L. Bentley, Jeremy P. Braude, Todd W. Mitchell, Adelle C.F. Coster, Anthony S. Don, et al.


  • Assaying Ceramide Synthase Activity In Vitro and in Living Cells Using Liquid Chromatography-Mass Spectrometry

    by Xin Ying Lim, Russell Pickford, Anthony S. Don

    Sphingolipids are one the major lipid families in eukaryotes, incorporating a diverse array of structural and signaling lipids such as sphingomyelin and gangliosides. The core lipid component for all complex sphingolipids is ceramide, a diacyl lipid consisting of a variable length fatty acid linked through an amide bond to a long chain base such as sphingosine or dihydrosphingosine. This reaction is catalyzed by a family of six ceramide synthases (CERS1-6), each of which preferentially catalyzes the synthesis of ceramides with different fatty acid chain lengths. Ceramides are themselves potent cellular and physiological signaling molecules heavily implicated in diabetes and neurodegenerative diseases, making it important for researchers to have access to sensitive and accurate assays for ceramide synthase activity. This chapter describes methods for assaying ceramide synthase activity in cell or tissue lysates, or in cultured cells (in situ), using liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the readout. LC-MS/MS is a very sensitive and accurate means for assaying ceramide synthase reaction products.


  • A Three‐Step Assay for Ceramide Synthase Activity Using a Fluorescent Substrate and HPLC

    by Timothy A. Couttas, Xin Y. Lim, Anthony S. Don

    Ceramides are a family of signalling lipids with diverse physiological functions that include pro‐differentiative and pro‐apoptotic signalling. Ceramides and their derivatives are major constituents of myelin, maintaining neuronal conductivity. Ceramides are synthesized by ceramide synthases, of which there are six isoforms in mammals (CERS1–6). These enzymes catalyse the transfer of a variable length fatty acid to a sphingoid base, typically sphingosine or dihydrosphingosine. We previously reported a fluorescent thin‐layer chromatography assay for ceramide synthase activity. In this paper we describe an improved fluorescent assay, using HPLC to achieve clear resolution of closely related ceramide species and to facilitate easy quantification of both product and substrate. Our HPLC assay protocol eliminates the need for a chloroform extraction step. Instead a simple three‐step procedure is used: (1) reactions are run; (2) reactions are terminated with addition of methanol and centrifuged; (3) products are quantified with HPLC. HPLC resolution enables assays in which multiple fatty acid substrates are used in the same reaction. Using this approach, we show that CERS2 demonstrates a preference for the monounsaturated C24:1 fatty acid substrate compared to the saturated C24:0 substrate, potentially explaining why myelin is enriched in ceramides containing the monounsaturated form of very long chain fatty acids.


  • Open Access

    Re-Configuration of Sphingolipid Metabolism by Oncogenic Transformation

    by Anthony S. Don, Xin Y. Lim, Timothy A. Couttas

    The sphingolipids are one of the major lipid families in eukaryotes, incorporating a diverse array of structural variants that exert a powerful influence over cell fate and physiology. Increased expression of sphingosine kinase 1 (SPHK1), which catalyses the synthesis of the pro-survival, pro-angiogenic metabolite sphingosine 1-phosphate (S1P), is well established as a hallmark of multiple cancers. Metabolic alterations that reduce levels of the pro-apoptotic lipid ceramide, particularly its glucosylation by glucosylceramide synthase (GCS), have frequently been associated with cancer drug resistance. However, the simple notion that the balance between ceramide and S1P, often referred to as the sphingolipid rheostat, dictates cell survival contrasts with recent studies showing that highly potent and selective SPHK1 inhibitors do not affect cancer cell proliferation or survival, and studies demonstrating higher ceramide levels in some metastatic cancers. Recent reports have implicated other sphingolipid metabolic enzymes such as acid sphingomyelinase (ASM) more strongly in cancer pathogenesis, and highlight lysosomal sphingolipid metabolism as a possible weak point for therapeutic targeting in cancer. This review describes the evidence implicating different sphingolipid metabolic enzymes and their products in cancer pathogenesis, and suggests how newer systems-level approaches may improve our overall understanding of how oncogenic transformation reconfigures sphingolipid metabolism.


  • Open Access

    Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis

    by Timothy A Couttas, Nupur Kain, Benjamin Daniels, Xin Ying Lim, Claire Shepherd, Jillian Kril, Russell Pickford, Hongyun Li, Brett Garner, Anthony S Don

    The greatest genetic risk factor for late-onset Alzheimer's disease (AD) is the ϵ4 allele of Apolipoprotein E (ApoE). ApoE regulates secretion of the potent neuroprotective signaling lipid Sphingosine 1-phosphate (S1P). S1P is derived by phosphorylation of sphingosine, catalysed by sphingosine kinases 1 and 2 (SphK1 and 2), and SphK1 positively regulates glutamate secretion and synaptic strength in hippocampal neurons. S1P and its receptor family have been subject to intense pharmacological interest in recent years, following approval of the immunomodulatory drug Fingolimod, an S1P mimetic, for relapsing multiple sclerosis.